期刊文献+

A HPLC-Q-TOF-MS-based Urinary Metabolomic Approach to Identification of Potential Biomarkers of Metabolic Syndrome 被引量:7

A HPLC-Q-TOF-MS-based Urinary Metabolomic Approach to Identification of Potential Biomarkers of Metabolic Syndrome
下载PDF
导出
摘要 Metabolic syndrome (MetS) is a serious threat to public health worldwide with an increased risk of developing type 2 diabetes, cardiovascular diseases and all-cause morbidity and mortality. In this study, a urinary metabolomic approach was performed on high performance liquid chromatography quadrupole time-of-flight mass spectrometry to discriminate 36 male MetS patients and 36 sex and age matched healthy controls. Pattern recognition analyses (principal component analysis and orthogonal projections to latent structures discriminate analysis) commonly demonstrated the difference between MetS patients and no-MetS subjects. This study found 8 metabolites that showed significant changes in patients with MetS, including branch-chain and aromatic amino acids (leucine, tyrosine, phenylalanine and tryptophan), short-chain acylcanitine (tiglylcamitine), tricarboxylic acid (TCA) cycle intermediate (cis-aconitic acid) and glucuronidated products (cortolone-3-glucuronide and tetrahydroaldoster- one-3-glucuronide). The candidate biomarkers revealed in this study could be useful in providing clues for further research focusing on the in-depth investigation of the cause of and cure for MetS. Metabolic syndrome (MetS) is a serious threat to public health worldwide with an increased risk of developing type 2 diabetes, cardiovascular diseases and all-cause morbidity and mortality. In this study, a urinary metabolomic approach was performed on high performance liquid chromatography quadrupole time-of-flight mass spectrometry to discriminate 36 male MetS patients and 36 sex and age matched healthy controls. Pattern recognition analyses (principal component analysis and orthogonal projections to latent structures discriminate analysis) commonly demonstrated the difference between MetS patients and no-MetS subjects. This study found 8 metabolites that showed significant changes in patients with MetS, including branch-chain and aromatic amino acids (leucine, tyrosine, phenylalanine and tryptophan), short-chain acylcanitine (tiglylcamitine), tricarboxylic acid (TCA) cycle intermediate (cis-aconitic acid) and glucuronidated products (cortolone-3-glucuronide and tetrahydroaldoster- one-3-glucuronide). The candidate biomarkers revealed in this study could be useful in providing clues for further research focusing on the in-depth investigation of the cause of and cure for MetS.
出处 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2014年第2期276-283,共8页 华中科技大学学报(医学英德文版)
基金 supported by a grant from the Tianjin Scientific and Technological Support Key Projects(No.08ZCGYSF01500) the Tianjin Department of Science&Technology
关键词 metabolic syndrome metabolomics HPLC-Q-TOF-MS urine biomarker metabolic syndrome metabolomics HPLC-Q-TOF-MS urine biomarker
  • 相关文献

参考文献38

  • 1Alberti KC~ Zimmet P, Shaw J. The metabolic syn- drome---a new worldwide definition. Lancet, 2005, 366(9491): 1059-1062.
  • 2Alberti KG; Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epide- miology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and In- ternational Association for the Study of Obesity. Circula- tion, 2009,120(16): 1640-1645.
  • 3Gu D, Reynolds K, Wu X, et al. Prevalence of the meta- bolic syndrome and overweight among adults in China. Lancet, 2005,365(9468): 1398-1405.
  • 4Gami AS, Witt B J, Howard DE, et al. Metabolic syn- drome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitu- dinal studies. J Am Coil Cardiol, 2007,49(4):403-414.
  • 5Kahn R, Buse J, Ferrannini E, et al. The metabolic syn- drome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2005,28(9):2289-2304.
  • 6Eckel RH, Alberti KG~ Grundy SM, et al. The metabolicsyndrome. Lancet, 2010,375(9710): 18 I- 183.
  • 7Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest, 2006,116(7): 1"J84-1792.
  • 8Esteghamati A, Zandieh A, Zandieh B, et al. Leptin cut-off values for determination of metabolic syndrome: third national surveillance of risk factors of non-commu- nicable diseases in Iran (SttRFNCD-2007). Endocrine, 2011,40(1):117-123.
  • 9Timpson N J, Lawlor DA, Harbord RM, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet, 2005,366(9501): 1954-1959.
  • 10Nicholson JK, Wilson ID. Opinion: understanding 'global' systems biology: metabonomics and the contin- uum of metabolism. Nat Rev Drug Discov, 2003,2(8): 668-676.

同被引文献43

  • 1Zhao-Hui Fang,Yan Liu,Tao-Tao Bao,Ying-Qun Ni,Jian Liu,Guo-Bin Shi,Ji-Ping Wu,Jun-Ping Yang,Hong Zhang.Effect of Danzhijiangtang capsule on monocyte chemoattractant protein-1 mRNA expression in newly diagnosed diabetes subclinical vascular lesions[J].World Journal of Gastroenterology,2013,19(19):2963-2968. 被引量:9
  • 2樊龙中,王昱,崔桂林,朱正洪,纪英萍,何俐勇,王平.尿液氨基酸代谢物和血清特异生长因子联检癌症临床应用[J].实用全科医学,2005,3(5):462-463. 被引量:3
  • 3陈颖,邵生文,深更新,姚永详,陈明.高效液相测定膨化食品中的诱惑红含量[J].中国民康医学,2006,18(19):837-838. 被引量:8
  • 4Srinivasan K, Viswanad B, Asrat L, et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening[J]. Pharmacol Res, 2005, 52(4): 313-320.
  • 5Paneni F, Beckman JA, Creager MA, et al. Diabetes and vas- cular disease: pathophysiology, clinical Consequences, and medical therapy., part I [J]. Eur Heart J, 2013, 34 (31) :2436 -2443.
  • 6Barton RH, Nicholson JK, Elliott P, etal. High-throughput 1H NMR-based metabolic analysis of human serum and urine for large-scale epiderniological studies: validation study[J]. Int J Epiderniol, 2008, 37(Suppl 1): i31-i40.
  • 7Tagore S, Chowdhury N, De RK. Analyzing methods for path mining with applications in metabolomics[ J]. Gene, 2014, 534(2) : 125-138.
  • 8Philip F, John W, Robert S, et al. Amino acid and protein metabolism in diabetes mellitus[J]. Arch Intern Med, 1997, 137(4) : 507-513.
  • 9Broderick TL, Haloftis G, Paulson DJ. L-propionylcarnitine enhancement of substrate oxidation and mitochondrial respira- tion in the diabetic rat heart[J]. J Mol Cell Cardiol, 1996, 28 (2) : 331-340.
  • 10Singh M, Feigelson M. Effects of maternal diabetes on the levels, synthetic rates and activities of synthetic enzymes of surface-active phospholipids in perinatal rat lung[J]. Biochim Biophys Acta, 4983, 753(1): 53-59.

引证文献7

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部